Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Price Target at $7.83

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned an average rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $7.83.

A number of equities analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, August 14th. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Monday, August 12th.

Institutional Trading of Aquestive Therapeutics

Several hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth about $27,000. SG Americas Securities LLC purchased a new position in shares of Aquestive Therapeutics in the first quarter worth about $54,000. Jump Financial LLC bought a new stake in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $60,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at approximately $76,000. Finally, Financial Advocates Investment Management boosted its holdings in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after buying an additional 14,000 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Trading Up 3.3 %

Shares of Aquestive Therapeutics stock opened at $4.95 on Thursday. The company has a market capitalization of $450.64 million, a P/E ratio of -11.79 and a beta of 2.84. The stock has a fifty day simple moving average of $3.93 and a 200 day simple moving average of $3.69. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the prior year, the company earned ($0.10) EPS. On average, analysts predict that Aquestive Therapeutics will post -0.47 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.